#### Edgar Filing: OSCIENT PHARMACEUTICALS CORP - Form 4

#### OSCIENT PHARMACEUTICALS CORP

Form 4 March 16, 2006

# FORM 4

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

**OMB** 3235-0287 Number:

Expires:

Check this box if no longer subject to Section 16.

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES** 

January 31, 2005 Estimated average

Form 4 or Form 5 obligations may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

burden hours per response... 0.5

**OMB APPROVAL** 

1(b).

(Print or Type Responses)

	Address of Reporting I R STEVEN M	Symbol OSCIE	2. Issuer Name <b>and</b> Ticker or Trading Symbol OSCIENT PHARMACEUTICALS CORP [OSCI]			5. Relationship of Reporting Person(s) to Issuer  (Check all applicable)		
(Last) 1000 WINT	(First) (M	(Month/	3. Date of Earliest Transaction (Month/Day/Year) 02/27/2006				Owner er (specify	
WALTHAM	(Street) M, MA 02451		endment, Date Origin onth/Day/Year)	al	6. Individual or Japplicable Line) _X_ Form filed by Form filed by Person		rson	
(City)	(State)	(Zip) Tab	le I - Non-Derivativ	Securities Ac	quired, Disposed o	f, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Transaction(A) or I	(A) or	Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common Stock (1)	02/27/2006		A 100,00	00 A \$0	142,934	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

#### Edgar Filing: OSCIENT PHARMACEUTICALS CORP - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	Expiration D (Month/Day	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (right to buy)	\$ 1.93	02/27/2006		A	250,000	(2)	02/26/2016	Common shares	250,000	

# **Reporting Owners**

Reporting Owner Name / Address	Relationships					
<b>rg</b>	Director	10% Owner	Officer	Other		
RAUSCHER STEVEN M 1000 WINTER ST. SUITE 2200 WALTHAM, MA 02451	X		CEO and President			

# **Signatures**

Robert E. Farrell, Jr. Corp Controller/Treasurer - Power of
Attny

\*\*Signature of Reporting Person

Date

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Restricted shares issued under the Company's 2001 incentive plan; 50% vest on November 30, 2006 and 50% vest on November 30, 2007
- (2) Issued under the Company's 2001 incentive plan; vest quarterly over 2 years from date of grant

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2